|
|
Vaccine Detail
|
p.DOM-WT1-37 DNA Vaccine |
| Vaccine Information |
- Vaccine Name: p.DOM-WT1-37 DNA Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007073
- Type: DNA vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: WT1
- WT1
gene engineering:
- Preparation: The vaccine used a p.DOM-peptide encoding a minimal tumor-derived major histocompatibility complex (MHC) class I-binding epitope downstream of a foreign sequence of tetanus toxin (Chaise et al., 2008).
- Description: This is for Leukemia Cancer(NCT01334060). A fusion DNA vaccine containing the first domain of fragment C (FrC) of tetanus toxin (TT865-1120) (p.DOM) fused to the human Wilms' Tumor gene-1 (WT1)-derived MHC class I-binding epitope WT1.37, with potential antitumor activity. Upon vaccination with p.DOM-WT1-37 DNA and subsequent electroporation, this vaccine may induce a WT1 epitope-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation in WT1-overexpressing cancer cells. WT1, a tumor associated antigen, is overexpressed in most types of leukemia and in a variety of solid cancers. The FrC of tetanus toxin contains the MHC II-binding sequence, p30, which induces T-helper cell activation for long-lasting immunity (Ottensmeier et al., 2016; NCIT_C96737).
|
| Host Response |
|
|
| References |
Chaise et al., 2008: Chaise C, Buchan SL, Rice J, Marquet J, Rouard H, Kuentz M, Vittes GE, Molinier-Frenkel V, Farcet JP, Stauss HJ, Delfau-Larue MH, Stevenson FK. DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance. Blood. 2008; 112(7); 2956-2964. [PubMed: 18502835].
NCIT_C96737: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C96737]
NCT01334060: [https://clinicaltrials.gov/show/NCT01334060]
Ottensmeier et al., 2016: Ottensmeier C, Bowers M, Hamid D, Maishman T, Regan S, Wood W, Cazaly A, Stanton L. Wilms’ tumour antigen 1 Immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation: a Phase II non-randomised clinical trial (WIN). NIHR Journals Library. 2016; ; . [PubMed: 27099895].
|
|
